{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:21:02Z","timestamp":1792783262826,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin. Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This survey collected global perspectives on the burden and management of hypophosphataemic osteomalacia in adults through the International Osteoporosis Foundation (IOF). The IOF network represents a valuable international resource for understanding the burden and management of rare bone disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the international burden and management of hypophosphataemic osteomalacia (HO) in adult patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A survey was developed consisting of seven questions about respondents and their experiences of managing HO, with a second section inviting additional non-identifying information on up to five patients. The survey was disseminated to the International Osteoporosis Foundation (IOF) network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty clinicians from 24 countries responded, with most based in academic centres. Respondents reported managing over 1000 adult patients with HO, primarily diagnosed with X-linked hypophosphataemia (XLH; 35%), tumour-induced osteomalacia (TIO; 24%), and fibrous dysplasia\/McCune\u2013Albright syndrome (FD\/MAS; 16%). Management varied by diagnosis, reflecting differences in the underlying pathophysiology and clinical manifestations of the disorders. Respondents provided additional information on 19 patients with XLH, 28 with TIO, and 9 with other HO disorders. Common symptoms across XLH and TIO included bone pain (XLH, 67%; TIO, 88%), muscle pain (XLH, 61%; TIO, 76%), and muscle weakness (XLH, 61%; TIO, 88%). Many patients with XLH had discontinued phosphate and vitamin D therapies, with a subset initiating burosumab treatment. In contrast, phosphate and vitamin D were commonly used in TIO, with many patients being considered for tumour resection and limited burosumab use. Pain medication use, including opiates, was relatively high across all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adults with HO experience a significant burden of musculoskeletal symptoms. Future efforts should focus on global education of healthcare professionals. The IOF network represents a valuable international resource for understanding the burden and management of rare bone disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01692-y","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:50:10Z","timestamp":1774885810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Global perspectives on the burden and management of hypophosphataemic osteomalacia in adult patients: an International Osteoporosis Foundation (IOF) survey"],"prefix":"10.1007","volume":"21","author":[{"given":"Maria Luisa","family":"Brandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Halbout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique D.","family":"Pierroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"1692_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jbmr.4486","volume":"37","author":"F Aljuraibah","year":"2022","unstructured":"Aljuraibah F, Bacchetta J, Brandi ML et al (2022) An expert perspective on phosphate dysregulation with a focus on chronic hypophosphatemia. J Bone Miner Res 37:12\u201320. https:\/\/doi.org\/10.1002\/jbmr.4486","journal-title":"J Bone Miner Res"},{"key":"1692_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1507\/endocrj.EJ15-0289","volume":"62","author":"S Fukumoto","year":"2015","unstructured":"Fukumoto S, Ozono K, Michigami T et al (2015) Pathogenesis and diagnostic criteria for rickets and osteomalacia &mdash; Proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]. Endocr J 62:665\u201371. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0289","journal-title":"Endocr J"},{"key":"1692_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314896","volume":"23","author":"L Cianferotti","year":"2022","unstructured":"Cianferotti L (2022) Osteomalacia is not a single disease. Int J Mol Sci 23. https:\/\/doi.org\/10.3390\/ijms232314896","journal-title":"Int J Mol Sci"},{"key":"1692_CR4","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.3390\/jcm12072714","volume":"12","author":"L Arboleya","year":"2023","unstructured":"Arboleya L, Bra\u00f1a I, Pardo E, Loredo M, Queiro R (2023) Osteomalacia in adults: a practical insight for clinicians. J Clin Med 12:2714. https:\/\/doi.org\/10.3390\/jcm12072714","journal-title":"J Clin Med"},{"key":"1692_CR5","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0564","volume":"11","author":"C Nguyen","year":"2022","unstructured":"Nguyen C, Celestin E, Chambolle D et al (2022) Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration. Endocr Connect 11. https:\/\/doi.org\/10.1530\/EC-21-0564","journal-title":"Endocr Connect"},{"key":"1692_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A et al (2019) The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 3:1321\u20131334. https:\/\/doi.org\/10.1210\/js.2018-00365","journal-title":"J Endocr Soc"},{"key":"1692_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/17423953211049436","volume":"18","author":"A Konradi","year":"2022","unstructured":"Konradi A (2022) Fibrous dysplasia patients with and without craniofacial involvement report reduced quality of life inclusive of stigma, depression, and anxiety. Chronic Illn 18:927\u2013936. https:\/\/doi.org\/10.1177\/17423953211049436","journal-title":"Chronic Illn"},{"key":"1692_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116064","volume":"152","author":"ML Brandi","year":"2021","unstructured":"Brandi ML, Clunie GPR, Houillier P et al (2021) Challenges in the management of tumor-induced osteomalacia (TIO). Bone 152. https:\/\/doi.org\/10.1016\/j.bone.2021.116064","journal-title":"Bone"},{"key":"1692_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae118","volume":"8","author":"N Namba","year":"2024","unstructured":"Namba N, Ito N, Michigami T et al (2024) Impact of X-linked hypophosphatemic rickets\/osteomalacia on health and quality of life: baseline data from the SUNFLOWER longitudinal, observational cohort study. JBMR Plus 8. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae118","journal-title":"JBMR Plus"},{"key":"1692_CR10","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1210\/clinem\/dgaf170","volume":"110","author":"AA Khan","year":"2025","unstructured":"Khan AA, Ali DS, Appelman-Dijkstra NM et al (2025) X-linked hypophosphatemia management in adults: an international working group clinical practice guideline. J Clin Endocrinol Metab 110:2353\u201370. https:\/\/doi.org\/10.1210\/clinem\/dgaf170","journal-title":"J Clin Endocrinol Metab"},{"key":"1692_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00198-023-06791-x","volume":"34","author":"M Chandran","year":"2023","unstructured":"Chandran M, Alves I, Carpenter T et al (2023) Improving care pathways for people living with rare bone diseases (RBDs): outcomes from the first RBD Summit. Osteoporos Int 34:1301\u201310. https:\/\/doi.org\/10.1007\/s00198-023-06791-x","journal-title":"Osteoporos Int"},{"key":"1692_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D et al (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14. https:\/\/doi.org\/10.1186\/s13023-019-1014-8","journal-title":"Orphanet J Rare Dis"},{"key":"1692_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK (2009) Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 160:491\u2013497. https:\/\/doi.org\/10.1530\/EJE-08-0818","journal-title":"Eur J Endocrinol"},{"key":"1692_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, R\u00e6der H, Bjerknes R (2016) Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174:125\u2013136. https:\/\/doi.org\/10.1530\/EJE-15-0515","journal-title":"Eur J Endocrinol"},{"key":"1692_CR15","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381\u20138. https:\/\/doi.org\/10.1002\/jbmr.340","journal-title":"J Bone Miner Res"},{"key":"1692_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41581-024-00926-x","volume":"21","author":"D Haffner","year":"2025","unstructured":"Haffner D, Emma F, Seefried L et al (2025) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 21:330\u201354. https:\/\/doi.org\/10.1038\/s41581-024-00926-x","journal-title":"Nat Rev Nephrol"},{"key":"1692_CR17","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1210\/clinem\/dgaf093","volume":"110","author":"DS Ali","year":"2025","unstructured":"Ali DS, Carpenter TO, Imel EA et al (2025) X-linked hypophosphatemia management in children: an international working group clinical practice guideline. J Clin Endocrinol Metab 110:2055\u201370. https:\/\/doi.org\/10.1210\/clinem\/dgaf093","journal-title":"J Clin Endocrinol Metab"},{"key":"1692_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","volume":"87","author":"SS Beck-Nielsen","year":"2010","unstructured":"Beck-Nielsen SS, Brusgaard K, Rasmussen LM et al (2010) Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 87:108\u201319. https:\/\/doi.org\/10.1007\/s00223-010-9373-0","journal-title":"Calcif Tissue Int"},{"key":"1692_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1172\/jci200318399","volume":"112","author":"M Riminucci","year":"2003","unstructured":"Riminucci M, Collins MT, Fedarko NS et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683\u2013692. https:\/\/doi.org\/10.1172\/jci200318399","journal-title":"J Clin Invest"},{"key":"1692_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2024.101772","volume":"21","author":"N \u00c1lvarez-Rivas","year":"2024","unstructured":"\u00c1lvarez-Rivas N, Lugo-Rodr\u00edguez G, Maneiro JR et al (2024) Tumor-induced osteomalacia: a systematic literature review. Bone Rep 21. https:\/\/doi.org\/10.1016\/j.bonr.2024.101772","journal-title":"Bone Rep"},{"key":"1692_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","volume":"108","author":"P Florenzano","year":"2021","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT (2021) Tumor-induced osteomalacia. Calcif Tissue Int 108:128\u2013142. https:\/\/doi.org\/10.1007\/s00223-020-00691-6","journal-title":"Calcif Tissue Int"},{"key":"1692_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.arcped.2021.09.005","volume":"28","author":"NAT Hamdy","year":"2021","unstructured":"Hamdy NAT, Harvengt P, Usardi A (2021) X-linked hypophosphatemia: the medical expert\u2019s challenges and the patient\u2019s concerns on their journey with the disease. Arch Pediatr 28:612\u2013618. https:\/\/doi.org\/10.1016\/j.arcped.2021.09.005","journal-title":"Arch Pediatr"},{"key":"1692_CR23","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","volume":"32","author":"S Giannini","year":"2021","unstructured":"Giannini S, Bianchi ML, Rendina D, Massoletti P, Lazzerini D, Brandi ML (2021) Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. Osteoporos Int 32:1937\u20131949. https:\/\/doi.org\/10.1007\/s00198-021-05997-1","journal-title":"Osteoporos Int"},{"key":"1692_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/clinem\/dgab796","volume":"107","author":"K Dahir","year":"2022","unstructured":"Dahir K, Dhaliwal R, Simmons J et al (2022) Health care transition from pediatric- to adult-focused care in X-linked hypophosphatemia: expert consensus. J Clin Endocrinol Metab 107:599\u2013613. https:\/\/doi.org\/10.1210\/clinem\/dgab796","journal-title":"J Clin Endocrinol Metab"},{"key":"1692_CR25","unstructured":"European Medicines Agency (2018) Orphan maintenance assessment report: Crysvita (recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23). Treatment of hypophosphataemic rickets. https:\/\/www.ema.europa.eu\/en\/documents\/orphan-maintenance-report\/crysvita-orphan-maintenance-assessment-report-initial-authorisation_en.pdf. Accessed 24 July 2025."},{"key":"1692_CR26","unstructured":"Kyowa Kirin (2018) Kyowa Kirin and Ultragenyx announce Crysvita\u00ae (burosumab) receives conditional marketing authorisation in Europe for the treatment of X\u2013linked hypophosphatemia in children. https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2018\/e20180223_01.html. Accessed 22 July 2025."},{"key":"1692_CR27","unstructured":"Kyowa Kirin (2020) Kyowa Kirin announces European Commission (EC) approval of CRYSVITA\u00ae (burosumab) for the treatment of X-linked hypophosphataemia (XLH) in older adolescents and adults. https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2020\/e20201005_01.html. Accessed 22 July 2025."},{"key":"1692_CR28","unstructured":"Kyowa Kirin (2022) Kyowa Kirin receives positive CHMP opinion for use of CRYSVITA\u00ae \u25bc(burosumab) for the treatment of tumour-induced osteomalacia (TIO). https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2022\/pdf\/e20220627_01.pdf. Accessed 22 July 2025."},{"key":"1692_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/joim.13593","volume":"293","author":"SM Jan de Beur","year":"2023","unstructured":"Jan de Beur SM, Minisola S, Xia WB et al (2023) Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med 293:309\u2013328. https:\/\/doi.org\/10.1111\/joim.13593","journal-title":"J Intern Med"},{"key":"1692_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1102-9","volume":"14","author":"MK Javaid","year":"2019","unstructured":"Javaid MK, Boyce A, Appelman-Dijkstra N et al (2019) Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS International Consortium. Orphanet J Rare Dis 14. https:\/\/doi.org\/10.1186\/s13023-019-1102-9","journal-title":"Orphanet J Rare Dis"},{"key":"1692_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02882-4","volume":"18","author":"G Ariceta","year":"2023","unstructured":"Ariceta G, Beck-Nielsen SS, Boot AM et al (2023) The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data. Orphanet J Rare Dis 18. https:\/\/doi.org\/10.1186\/s13023-023-02882-4","journal-title":"Orphanet J Rare Dis"},{"key":"1692_CR32","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00198-022-06432-9","volume":"33","author":"S Minisola","year":"2022","unstructured":"Minisola S, Barlassina A, Vincent SA, Wood S, Williams A (2022) A literature review to understand the burden of disease in people living with tumour-induced osteomalacia. Osteoporos Int 33:1845\u20131857. https:\/\/doi.org\/10.1007\/s00198-022-06432-9","journal-title":"Osteoporos Int"},{"key":"1692_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116111","volume":"153","author":"J H\u00f6ppner","year":"2021","unstructured":"H\u00f6ppner J, Kornak U, Sinningen K, Rutsch F, Oheim R, Grasemann C (2021) Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) due to ENPP1-deficiency. Bone 153. https:\/\/doi.org\/10.1016\/j.bone.2021.116111","journal-title":"Bone"},{"key":"1692_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03036-w","volume":"19","author":"K Song","year":"2024","unstructured":"Song K, Shrestha R, Delaney H et al (2024) Diagnostic journey for individuals with fibrous dysplasia \/ McCune Albright syndrome (FD\/MAS). Orphanet J Rare Dis 19. https:\/\/doi.org\/10.1186\/s13023-024-03036-w","journal-title":"Orphanet J Rare Dis"},{"key":"1692_CR35","unstructured":"XLH Network Inc (2019) Voice of the patient report. https:\/\/xlhnetwork.org\/wp-content\/uploads\/2023\/05\/VOP-XLH-Final.pdf. Accessed 22 July 2025."},{"key":"1692_CR36","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1210\/clinem\/dgae890","volume":"110","author":"DS Ali","year":"2025","unstructured":"Ali DS, Mirza RD, Alsarraf F et al (2025) Systematic review: efficacy of medical therapy on outcomes important to adult patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 110:1767\u201380. https:\/\/doi.org\/10.1210\/clinem\/dgae890","journal-title":"J Clin Endocrinol Metab"},{"key":"1692_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/jendso\/bvab099","volume":"5","author":"K Dahir","year":"2021","unstructured":"Dahir K, Zanchetta MB, Stanciu I et al (2021) Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc 5:1\u20132. https:\/\/doi.org\/10.1210\/jendso\/bvab099","journal-title":"J Endocr Soc"},{"key":"1692_CR38","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(24)01305-9","volume":"404","author":"P Kamenick\u00fd","year":"2024","unstructured":"Kamenick\u00fd P, Briot K, Munns CF, Linglart A (2024) X-linked hypophosphataemia. Lancet 404:887\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(24)01305-9","journal-title":"Lancet"},{"key":"1692_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10580","volume":"6","author":"J DeCorte","year":"2022","unstructured":"DeCorte J, Randazzo E, Black M et al (2022) Rare diseases that impersonate one another: X-linked hypophosphatemia and tumor-induced osteomalacia, a retrospective analysis of discriminating features. JBMR Plus 6. https:\/\/doi.org\/10.1002\/jbm4.10580","journal-title":"JBMR Plus"},{"key":"1692_CR40","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P, Hendrickson C, Dahir K (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res 34:2183\u20132191. https:\/\/doi.org\/10.1002\/jbmr.3843","journal-title":"J Bone Miner Res"},{"key":"1692_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001714","volume":"7","author":"K Briot","year":"2021","unstructured":"Briot K, Portale AA, Brandi ML et al (2021) Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 7. https:\/\/doi.org\/10.1136\/rmdopen-2021-001714","journal-title":"RMD Open"},{"key":"1692_CR42","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/jpc.70015","volume":"61","author":"JL Sandy","year":"2025","unstructured":"Sandy JL, Biggin A, Siafarikas A et al (2025) X-linked hypophosphataemia and burosumab: a systemic disease with a new treatment. J Paediatr Child Health 61:685\u2013700. https:\/\/doi.org\/10.1111\/jpc.70015","journal-title":"J Paediatr Child Health"},{"key":"1692_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/JPR.S105892","volume":"9","author":"M Due\u00f1as","year":"2016","unstructured":"Due\u00f1as M, Ojeda B, Salazar A, Mico JA, Failde I (2016) A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res 9:457\u2013467. https:\/\/doi.org\/10.2147\/JPR.S105892","journal-title":"J Pain Res"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01692-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01692-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:32:47Z","timestamp":1776267167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01692-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01692-y","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study as no personal identifying information was collected, and all survey responses were completely anonymous.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"MLB: Consultancy fees and research grant from Kyowa Kirin. PH: None. DDP: None. NCH: Personal fees, consultancy, lecture fees, and\/or honoraria from Alliance for Better Bone Health, Amgen, Consilient Healthcare, Eli Lilly, Internis Pharma, Kyowa Kirin, MSD, Servier, Shire, Theramex, and UCB and outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"61"}}